No Clinically Significant Interaction Between Lenacapavir and Methadone or Heroin
Lenacapavir does not have documented clinically significant drug-drug interactions with methadone or heroin (diacetylmorphine), and these medications can be used together without dose adjustments. 1
Pharmacologic Basis
Lenacapavir is primarily metabolized via CYP3A (minor pathway) and UGT1A1 (minor pathway), with no single metabolic pathway predominating 1. The drug acts as a moderate CYP3A inhibitor but does not significantly interact with opioid metabolism pathways 1.
Key Metabolic Considerations:
- Methadone is metabolized primarily through CYP3A4, CYP2B6, and CYP2D6
- Heroin (diacetylmorphine) is rapidly converted to morphine through non-CYP enzymatic hydrolysis
- Lenacapavir's moderate CYP3A inhibition is insufficient to cause clinically meaningful changes in methadone or heroin metabolism
FDA Labeling Guidance
The lenacapavir prescribing information does not list methadone or heroin among contraindicated or cautionary drug interactions 1. The FDA label specifically addresses:
- Contraindications: Strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin)
- Not recommended: Moderate CYP3A inducers, combined P-gp/UGT1A1/strong CYP3A inhibitors
- Monitoring required: Sensitive CYP3A substrates with narrow therapeutic indices (e.g., midazolam, quetiapine)
Opioids are notably absent from these categories 1.
Clinical Context from HIV Treatment Guidelines
Recent evidence from HIV PrEP and treatment studies supports safe co-administration:
- The PURPOSE-1 and PURPOSE-2 trials establishing lenacapavir efficacy did not exclude persons using opioids 2, 3
- Clinical recommendations for lenacapavir PrEP make no mention of opioid interactions or dose modifications 2
- Real-world case series of lenacapavir drug interactions have not reported opioid-related adverse events 4
Comparison to Other Antiretrovirals
Historical data from hepatitis C treatment provides useful context. DAA (direct-acting antiviral) studies in persons on opioid substitution therapy demonstrated:
- No clinically important interactions between most DAAs and methadone or buprenorphine 5
- The only documented interaction was with ritonavir-boosted regimens (not applicable to lenacapavir) 5
Practical Management Recommendations
For patients on methadone:
- Initiate lenacapavir using standard dosing (Day 1: 927 mg SC + 600 mg PO; Day 2: 600 mg PO; then 927 mg SC every 6 months) 2
- No methadone dose adjustment required
- Monitor for standard opioid effects (sedation, respiratory depression) as you would without lenacapavir
For patients using heroin:
- Lenacapavir can be safely initiated without concern for pharmacokinetic interactions
- Focus on standard harm reduction strategies and consideration of medication-assisted treatment 6
- The long half-life of lenacapavir (8-12 weeks after SC injection) provides sustained HIV protection despite variable heroin use patterns 1
Important Caveats
Lenacapavir's CYP3A Inhibition Effects
While lenacapavir does not significantly affect methadone or heroin, it can increase concentrations of other medications metabolized by CYP3A for up to 9 months after the last subcutaneous dose 1. This is relevant for:
- Fentanyl (synthetic opioid, CYP3A substrate) - theoretical interaction, though not documented in clinical studies
- Benzodiazepines (e.g., midazolam) - documented 3-4 fold increase in exposure 1
Clinical pearl: The combination of opioids plus benzodiazepines carries high overdose risk regardless of lenacapavir 7. If a patient on lenacapavir requires benzodiazepines, use reduced doses and monitor closely.
Monitoring Considerations
Standard monitoring for lenacapavir includes:
- Injection site reactions (most common adverse effect - nodules, pain, induration) 2
- No specific laboratory monitoring required for opioid interactions
- Continue routine monitoring for opioid use disorder if applicable (urine drug testing, treatment agreements) 7
Research Gaps
A recent comprehensive review identified the need for more data on lenacapavir-opioid interactions 8, but the absence of documented interactions in clinical trials and post-marketing surveillance supports current safe co-administration practices. The theoretical framework suggests minimal risk given non-overlapping metabolic pathways.